PAD Research Network

A Collaborative Research Network including Brigham and Women's Hospital and Dartmouth Hitchcock Medical Center - A Center in the AHA SFRN for Vascular Disease

[CPC Clinical Research @cpcresearch]

For all those in Philadelphia at #AHA23 - 🔔take the liberty to go catch Dr. Mario Canonico present “Impact of Low-Dose Rivaroxaban Plus Aspirin on Total Vascular Events in Fragile Patients With Peripheral Artery Disease: Insights From VOYAGER PAD” at 2:15 PM ET in 103B!

[Cleerly @Cleerlyhealth]

In collaboration with our partners, we’re thrilled to announce the TRANSFORM trial, a cutting-edge study aiming to prove the benefits of personalized care strategies for heart disease. Learn more here: https://t.co/GuntokxY9n #CardiacCare

[CPC Clinical Research @cpcresearch]

#ICYMI Dr. @MarcBonaca presented #Featured Insights from #VOYAGERPAD at #AHA2020
View the slide deck & the presentation here:
https://t.co/aZ2uvid4tP

[CPC Clinical Research @cpcresearch]

It is with great sadness we share the news that Dr. @WilliamHiatt18 passed away peacefully on 8Dec2020. Read our full tribute to our beloved friend, mentor, and leader @ https://t.co/F9A2KTKFsV
Initiatives to celebrate Will’s legacy will be shared in the near future.
#RIPDrHiatt

[CPC Clinical Research @cpcresearch]

As we remember the remarkable life of Dr. Will Hiatt- Integrity was the cornerstone that he built his life around. But as always, he said it best in his own words. This was the last thing he wrote on his white board...
#RIPDrHiatt
Read our full tribute at https://t.co/OdXl7UlKK1

[LA McKeown @lamckeown1]

Remembering Dr. Hiatt. @JoshuaBeckmanMD @MarcBonaca #PAD https://t.co/oTM2iHjZ4K

[PAD Research Network @NetworkPad]

A true giant in the field of vascular medicine

[CPC Clinical Research @cpcresearch]

As we remember the remarkable life of Dr. Will Hiatt- Integrity was the cornerstone that he built his life around. But as always, he said it best in his own words. This was the last thing he wrote on his white board...
#RIPDrHiatt
Read our full tribute at https://t.co/OdXl7UlKK1

[Marc Bonaca MD MPH @MarcBonaca]

Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety https://t.co/PEsZfe4ab5 @WillHiatt @cpcresearch

[PAD Research Network @NetworkPad]

https://t.co/t4lMJkJoI4

[NEJM @NEJM]

Original Article: Rivaroxaban in Peripheral Artery Disease #ACC20 #WCCardio

[TIMI Study Group @TIMIStudyGroup]

See the poster: Ticagrelor And Major Adverse Limb Events: A Systemic Review And Meta-Analysis, available now. #ACC20Virtual

[VascularMedicine @VMJ_SVM]

From the masters: A sea-change for TransAtlantic Inter-Society Consensus (TASC). Updating #PAD guidelines for the modern era @WilliamHiatt18
#onlinefirst

https://t.co/u98RFcoAUQ

[CPC Clinical Research @cpcresearch]

If you enjoyed our 1st #LBCT today then we know your looking forward to our next one tomorrow at 11:15 AM CDT. CPC’s @WilliamHiatt18 will be answering the now popular question-Did background clopidogrel modify the efficacy or safety of rivaroxaban? https://t.co/18400s1XCE
#ACC20

[ACC Media Center @ACCmediacenter]

#cvPAD patients taking rivaroxaban + aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15% reduction in risk of adverse events than those taking aspirin alone, new #ACC20/#WCCardio research by Dr. @MarcBonaca finds: https://t.co/TXCD6N8xZV

[Dr Roxana Mehran @Drroxmehran]

#VOYEGAR #ACC2020 largest study on lower extremity revasc shows riva 2.5mg BID+ASA reduces limb, brain, and cardiovascular events at three years (NNT=39), increased bleeding, but not Intracranial or TIMI Major bleeding, but ISTH bleeds increased (NNH-125).A win for the right pts

[Geoff Barnes @GBarnesMD]

I agree with @JoshuaBeckmanMD that it is critical for all "cardiologists" to embrace the "vascular" aspect of our cardiovascular medicine training by screening for and treating #PAD... examine feet/pulses, start statins, initiate #smoking cessation, and discuss ASA+riva #ACC2020

[American College of Cardiology @ACCinTouch]

Excitement is building for #ACC20/#WCCardio which kicks off TOMORROW at 8:00 a.m. CT. Join us for three days of Late-Breaking Clinical Trials, Featured Clinical Research, Young Investigator Awards, Keynotes, and much, much more. https://t.co/iuLAZcmhLs

[CPC Clinical Research @cpcresearch]

We are 2 days away until VOYAGER PAD results are presented at #ACC2020 – View this Late-Breaker Presentation LIVE on Saturday, March 28th at 9:00 AM CDT at https://t.co/18400s1XCE to help us understand how to best care for patients with #PAD
@MarcBonaca @WilliamHiatt18

[CPC Clinical Research @cpcresearch]

Join us LIVE for Virtual #ACC2020 on Saturday March 28th at 9:20 CT for @MarcBonaca's presentation of Rivaroxaban For Prevention Of Cardiovascular And Limb Events After Lower Extremity Revascularization: Primary Results Of The Voyager Pad Randomized Trial
https://t.co/sf3afU07eQ

[Marc Bonaca MD MPH @MarcBonaca]

PAD patients after revascularization are at very high risk of limb and cardiovascular complications and never return to the risk profile of PAD patients with no history of revasc. Better therapies are needed to reduce this risk @WilliamHiatt18 @cpcresearch